Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.

Détails

ID Serval
serval:BIB_AD86B7A32BB2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
Périodique
European Journal of Internal Medicine
Auteur⸱e⸱s
Engelberger R.P., Noll G., Schmidt D., Alatri A., Frei B., Kaiser W.E., Kucher N.
ISSN
1879-0828 (Electronic)
ISSN-L
0953-6205
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
26
Numéro
7
Pages
508-514
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
BACKGROUND: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known.
METHODS: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up.
RESULTS: We enrolled 537 patients (73±11years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2±1.3 and 2.4±1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naïve (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6±1.4 under VKA to 5.5±0.8 points (P<0.001), and overall physician satisfaction from 3.9±1.3 to 5.4±0.9 points (P<0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4±0.9) and physician's satisfaction (5.5±0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95%CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95%CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95%CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason.
CONCLUSION: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction.
Mots-clé
Aged, Aged, 80 and over, Atrial Fibrillation/complications, Factor Xa Inhibitors/adverse effects, Factor Xa Inhibitors/therapeutic use, Female, Hemorrhage/chemically induced, Humans, Male, Middle Aged, Primary Health Care, Prospective Studies, Risk Factors, Rivaroxaban/adverse effects, Rivaroxaban/therapeutic use, Stroke/drug therapy, Stroke/prevention & control, Switzerland, Treatment Outcome, Vitamin K/antagonists & inhibitors, Vitamin K/therapeutic use
Pubmed
Web of science
Création de la notice
03/01/2016 17:48
Dernière modification de la notice
03/06/2020 6:26
Données d'usage